Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Central Nervous System Lymphoma Initial Diagnosed as Tumefective Multiple Sclerosis after Brian Biopsy
Intern Med 52:483-488, Ohe, Y.,et al, 2013
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009
The MRI Appearance of Tumefactive Demyelinating Lesions
AJR 182:195-199, Given II,C.A.,et al, 2004
Sandlike Appearance of Virchow-Robin Spaces in Early Multiple Sclerosis:A Novel Neuroradiologic Marker
AJNR 23:376-380, Achiron,A.&Faibel,M., 2002
Proton MR Spectroscopy of Tumefactive Demyelinating Lesions
AJNR 23:1378-1386, Saindane,A.M.,et al, 2002
Physiologic MRI of a Tumefactive Multiple Sclerosis Lesion
Neurol 51:1487-1488, Ernst,T.,et al, 1998
Large Focal Tumor-Like Demyelinating Lesions of the Brain:Intermed Entity Between MS & Acute Dissem Encephalomyelitis?
Ann Neurol 33:18-27, Kepes,J.J., 1993
Multiple Sclerosis Masquerading as a Mass Lesion
Neuroradiolgoy 34:150-154, Giang,D.W.,et al, 1992
Multiple Sclerosis Simulating Brain Tumor on Computed Tomography
J Comput Assist Tomogr 13:674-678, Otsuka,S.I.,et al, 1989
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
A 55-Year-Old Woman with Recurrent Episodes of Aphasia and Vision Changes
Neurol 98:330-335, Jeanneret, V.,et al, 2022
The Boston Criteria Version 2.0 for Cerebral Amylois Angiopathy:A Multicentre, Retrospective, MRI-Neuropathology Diagnostic Accuracy Study
Lancet Neurol 21:714-725, Charidimou,A.,et al, 2022
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
Tumefactive Primary Central Nervous System Vasculitis:Imaging Findings of a Rare and Underrecognized Neuroinflammatory Disease
AJNR 41:2075-2081, Suthiphosuwan,S.,et al, 2020
"Better Explanations" in Multiple Sclerosis Diagnostic Workup
Neurol 92:e2527-e2537, Calabrese, M.,et al, 2019
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Primary Angiitis of the Central Nervous System
Stroke 48:1248-1255, Boulouis, G.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Incidence of Radiologically Isolated Syndrome: A Population-Based Study
AJNR 37:1017-1022, Forslin, Y.,et al, 2016
Tumor-Like Presentation of Primary Angiitis of the Central Nervous System
Stroke 47:2401-2404, Boysson, H.,et al, 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Spectrum of Imaging Appearances of Intracranial Cryptococcal Infection in HIV/AIDS Patients in the Anti-Retroviral Therapy Era
Clin Radiol 71:9-17, Offiah, C.E. & Naseer, A., 2016
Investigation of Leptomeningeal Enhancement in MS
Neurol 84:770-775, Eisele, P.,et al, 2015
Swiss Cheese Striatum
Neurohosp doi:1941874415586193, Finelli, P.F., 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
MRI Characteristics of Neuromyelitis Optica Spectrum Disorder
Neurol 84:1165-1173, Jin Kim, H.,et al, 2015
White Matter Perivascular Spaces
Neurol 82:57-62, Charidimou, A.,et al, 2014